E-LIB Suche - Ergebnisse für: van de Donk, Niels W. C. J.

1

Loss of vision as the first manifestation of amyloid light‐..:

van de Donk, Niels W. C. J. ; Huysentruyt, Clément ; Dhooge, Mario R. P.
eJHaem. 5 (2024) 3 - p. 627-628 , 2024

Link: https://doi.org/10.1002/..

2

Clinical Management of Patients With Relapsed/Refractory Mu..:

Chari, Ajai ; Krishnan, Amrita ; Rasche, Leo...
Clinical Lymphoma Myeloma and Leukemia. , 2024

Link: https://doi.org/10.1016/..

3

Comparative Efficacy of Talquetamab vs. Current Treatments ..:

Einsele, Hermann ; Moreau, Philippe ; Bahlis, Nizar...
Advances in Therapy. 41 (2024) 4 - p. 1576-1593 , 2024

Link: https://doi.org/10.1007/..

4

Pharmacodynamic changes in tumor and immune cells drive ibe..:

Amatangelo, Michael ; Flynt, Erin ; Stong, Nicholas...
Cell Reports Medicine. 5 (2024) 6 - p. 101571 , 2024

Link: https://doi.org/10.1016/..

5

International Myeloma Working Group immunotherapy committee..:

Rodriguez-Otero, Paula ; Usmani, Saad ; Cohen, Adam D...
The Lancet Oncology. 25 (2024) 5 - p. e205-e216 , 2024

Link: https://doi.org/10.1016/..

6

Assessing frailty in myeloma: The pursuit of simplicity may..:

Groen, Kazimierz ; Smits, Febe ; Nasserinejad, Kazem...
HemaSphere. 8 (2024) 7 - p. , 2024

Link: https://doi.org/10.1002/..

7

Practical Aspects of Immunotherapy: A Report from the 20th ..:

Raje, Noopur S. ; Cohen, Adam D. ; Patel, Krina K....
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) 6 - p. 350-357 , 2024

Link: https://doi.org/10.1016/..

8

Teclistamab Improves Patient-Reported Symptoms and Health-R..:

Martin, Thomas G. ; Moreau, Philippe ; Usmani, Saad Z....
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) 3 - p. 194-202 , 2024

Link: https://doi.org/10.1016/..

9

Correlation of immune fitness with response to teclistamab ..:

Cortes-Selva, Diana ; Perova, Tatiana ; Skerget, Sheri...
Blood Journal. , 2024

Link: https://doi.org/10.1182/..

10

The Phase 2 Cartitude-2 Trial: Updated Efficacy and Safety ..:

Hillengass, Jens ; Cohen, Adam D. ; Agha, Mounzer...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S36-S37 , 2024

Link: https://doi.org/10.1016/..

11

GPRC5D as a novel target for the treatment of multiple myel..:

Rodriguez-Otero, Paula ; van de Donk, Niels W. C. J. ; Pillarisetti, Kodandaram...
Blood Cancer Journal. 14 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

12

Correction: GPRC5D as a novel target for the treatment of m..:

Rodriguez-Otero, Paula ; van de Donk, Niels W. C. J. ; Pillarisetti, Kodandaram...
Blood Cancer Journal. 14 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

13

Clinical Experience with Cranial Nerve Impairment in the Ca..:

van de Donk, Niels W.C.J. ; Sidana, Surbhi ; Schecter, Jordan M...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S380-S381 , 2024

Link: https://doi.org/10.1016/..

14

P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL..:

Moreau, Philippe ; van de Donk, Niels W.C.J. ; Delforge, Michel...
HemaSphere. 7 (2023) S3 - p. e690758f , 2023

Link: https://doi.org/10.1097/..

15

T-cell-engaging bispecific antibodies in cancer:

van de Donk, Niels W C J ; Zweegman, Sonja
The Lancet. 402 (2023) 10396 - p. 142-158 , 2023

Link: https://doi.org/10.1016/..